Is GlycoMimetics, Inc. overvalued or undervalued?

As of 28 April 2022, the valuation grade for GlycoMimetics, Inc. moved from risky to does not qualify, indicating a significant shift in its financial standing. The company is currently considered overvalued given its negative financial metrics, including a P/E ratio that is not applicable due to losses, a Price to Book Value of 3.71, and an ROE of -650.50%.
In comparison to its peers, GlycoMimetics shows a stark contrast; for instance, Eton Pharmaceuticals, Inc. has a P/E of -92.8956, while Abeona Therapeutics, Inc. has a P/E of -4.5154, both indicating substantial challenges within the sector. The company's recent stock performance has been volatile, with a 1-month return of 6165.36%, significantly outpacing the S&P 500's 3.83% return, yet this does not alter the overall valuation perspective.